Adedinsewo AI-ECG (peripartum cardiomyopathy)
2024
Artificial Intelligence Guided Screening for Cardiomyopathies in an Obstetric Population: a Pragmatic Randomized Clinical Trial
In 1,232 pregnant and postpartum women in Nigeria, AI-guided screening with a digital stethoscope and AI-ECG improved identification of left ventricular systolic dysfunction compared with usual care.
Result
Efficacy: Identification of left ventricular systolic dysfunction during the study periodOR 2.12 (95% CI 1.05-4.27) · P = 0.032
Below 1 favours usual care, above 1 favours AI-guided screening with a digital stethoscope and AI-ECG.
- Absolute difference
- 2.1 points
- NNT
- 48
Absolute difference and NNT are derived from the event rates.
Also reported: 12-lead AI-ECG: 3.4% (20/587) vs 2.0% (OR 1.75, 95% CI 0.85–3.62; P=0.125). 1,195 of 1,232 randomised completed the baseline visit; no serious adverse events.
- Subtopic
- Heart failure & cardiomyopathy
- Design
- Open-label pragmatic RCT, Nigeria (6 hospitals)
- Relevance
- Important: one of several pillars.
- Source
- Adedinsewo DA, et al. Nat Med. 2024;30(10):2897-2906.doi 10.1038/s41591-024-03243-9
Discussion & critique
The first randomised trial of AI screening in pregnancy, run in the country with the highest reported incidence of peripartum cardiomyopathy and a rare AI trial in a low-resource setting. Only the digital-stethoscope model reached significance; the 12-lead AI-ECG did not. The endpoint is detection rather than maternal outcome, the trial was open-label, and the intervention arm had a baseline confirmatory echocardiogram that the control arm did not, which favours detection in that arm.